Back to results
US 2023/0058588 A1Published application
Circulating microrna as a marker for hepatocellular carcinoma
AssigneeQuest Diagnostics Investments Incorporated
InventorsKevin Qu, Ke Zhang, Maher Albitar
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for the diagnosis, or management of liver diseases, e.g.. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.
Claims16
1-29. (canceled)
A method comprising:
- (a) detecting a level of miR-199a miRNA in a serum sample from a human subject diagnosed as having hepatocellular carcinoma (HCC), wherein the serum sample is obtained from the subject prior to administration of an anti-cancer therapy, by:
- (i) performing real-time reverse transcription polymerase chain reaction (RT-PCR) on the serum sample of (a) to measure a Ct value for miR-199a miRNA and a control Ct value for U6 small RNA, wherein the Ct value is measured using a detectably labeled probe specific for each miRNA assayed;
- and
- (ii) calculating a delta Ct value by subtracting the U6 control Ct value from the miR-199a Ct value;
- (b) detecting a level of miR-199a miRNA in a serum sample from the human subject diagnosed as having HCC, wherein the serum sample is obtained from the subject at a time point following to administration of the anti-cancer therapy, by:
- (i) performing real-time reverse transcription polymerase chain reaction (RT-PCR) on the serum sample of (b) to measure a Ct value for miR-199a miRNA and a control Ct value for U6 small RNA, wherein the Ct value is measured using a detectably labeled probe specific for each miRNA assayed;
- and
- (ii) calculating a delta Ct value by subtracting the U6 control Ct value from the miR-199a Ct value;
- and
- (c) comparing the delta Ct value of (a)(ii) to the delta Ct value of (b)(ii).
7 more elements
Dependencies are inferred from the claim text.